Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Summary by Charleston Gazette-Mail
Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation controlSustained clinical response to…

42 Articles

The Courier-TribuneThe Courier-Tribune
+41 Reposted by 41 other sources
Center

BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation controlSustained clinical response to…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 78% of the sources are Center
78% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Saturday, October 25, 2025.
Sources are mostly out of (0)

Similar News Topics

Asheboro icon

Asheboro

News
For You
SearchBlindspotLocal